“Ipsen establishes optimal biological dose for BN83495 steroid sulphatase (STS) inhibitor in ER-positive metastatic breast cancer” (Press release issued by Ipsen)
“FDA Meets Fewer PDUFA Dates in Fiscal 2008” (FDA News Bulletin)
“EU Pharma Reorganization Leaves Questions About How R&D Will Be Supported” (The Pink Sheet)
This is copyright protected information, to receive the full article, please click here to sign up and register.
“CDER’s Generational Shift: Many New Reviewers With Little Experience” (Health News Daily)
This is copyright protected information, to receive the full article, please click here to sign up and register.
“Approval Of Novartis’ Everolimus Could Mean mTOR Inhibitor Class REMS” (The Pink Sheet)
This is copyright protected information, to receive the full article, please click here to sign up and register.
“Bristol-Myers Finance Chief Huet To Depart At Year’s End” (CNN Money)
“AstraZeneca hit by Crestor court decision as panel evaluates Jupiter data” (PharmaTimes)
“ARIAD Announces Updated Data from Clinical Trial of Its Investigational mTOR Inhibitor, Ridaforolimus, In Combination with Trastuzumab” (GEN News)
“Pulse Electronic Health Record Solution is First to Receive Full CCHIT 2011 Comprehensive Certification” (BusinessWire)
SUBSCRIBE